Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M357Revenue (TTM) $M24.6Net Margin (%)-472.8Altman Z-Score-7.4
Enterprise Value $M388EPS (TTM) $-1.4Operating Margin %-430.1Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.7Pre-tax Margin (%)-494.7Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %-23.9Quick Ratio3.1Cash flow > EarningsY
Price/Sales14.05-y EBITDA Growth Rate %4.9Current Ratio3.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-54.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-310.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M87.1ROIC % (ttm)-1,248.5Gross Margin Increase y-yN

Gurus Latest Trades with AGEN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AGENRobert Bruce 2016-09-30 Reduce-0.09%$4.21 - $7.2
($5.84)
$ 4.10-30%Reduce -33.33%155,677
AGENKen Fisher 2016-09-30 Reduce$4.21 - $7.2
($5.84)
$ 4.10-30%Reduce -32.84%62,549
AGENKen Fisher 2016-06-30 Add$3.01 - $4.68
($3.97)
$ 4.103%Add 1.64%93,132
AGENKen Fisher 2015-09-30 Buy $4.43 - $9.44
($7.57)
$ 4.10-46%New holding91,632
AGENFirst Eagle Investment 2014-06-30 Sold Out -0.0017%$2.41 - $3.61
($2.94)
$ 4.1039%Sold Out0
AGENGeorge Soros 2014-06-30 Sold Out $2.41 - $3.61
($2.94)
$ 4.1039%Sold Out0
AGENFirst Eagle Investment 2014-03-31 Buy $2.64 - $5.1
($3.52)
$ 4.1016%New holding200,000
AGENGeorge Soros 2014-03-31 Buy $2.64 - $5.1
($3.52)
$ 4.1016%New holding102,200
AGENRobert Bruce 2012-06-30 Buy 0.52%$4.84 - $6.9
($5.78)
$ 4.10-29%New holding233,515
AGENRobert Bruce 2010-12-31 Buy $5.34 - $6.48
($5.71)
$ 4.10-28%New holding233,517
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AGEN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AGEN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
WIINBERG ULFDirector 2016-09-06Buy30,000$6.29-34.82view
ARMEN GARO HChairman & CEO 2016-05-09Buy100,000$3.1828.93view
ARMEN GARO HChairman & CEO 2016-05-09Buy100,000$3.1828.93view
Baysal OzerChief Business Officer 2016-05-05Buy2,250$3.132.26view
ARMEN GARO HChairman & CEO 2016-03-07Buy200,000$4.031.74view
ARMEN GARO HChairman & CEO 2015-12-29Sell219,576$4.59-10.68view
ARMEN GARO HChairman & CEO 2015-09-25Buy100,000$5.03-18.49view
Ballantyne Charles EvanCFO 2015-09-25Buy10,000$5.05-18.81view
Malik ShahzadDirector 2015-04-29Sell1,107,377$7.11-42.33view
QVT Associates GP LLC10% Owner 2015-01-09Sell2,343,630$5.31-22.79view

Quarterly/Annual Reports about AGEN:

News about AGEN:

Articles On GuruFocus.com
Weekly CEO Buys Highlights Mar 14 2016 
Paul Tudor Jones' Highest Performing Stocks Jul 13 2015 
Agenus Inc.: Ingeniously Designed Vaccines To Galvanized Tomorrow's Medicine Jul 25 2014 
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
Weekly CEO Buys Highlight: CTAS, VRX, TAT, AGEN, MRK Aug 20 2011 
Chairman & CEO of Agenus Inc. (AGEN) Garo Armen Buys 2,150,976 Shares Aug 18 2011 
Antigenics Inc. Reports Operating Results (10-K) Mar 16 2011 
Antigenics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 1,500 Shares Oct 28 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 2,000 Shares Sep 14 2010 

More From Other Websites
Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody... Dec 01 2016
Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors Dec 01 2016
Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody... Nov 30 2016
AGENUS INC Financials Nov 17 2016
ETFs with exposure to Agenus, Inc. : November 16, 2016 Nov 16 2016
Agenus to Present at the Jefferies 2016 London Healthcare Conference Nov 14 2016
AGENUS INC Files SEC form 10-Q, Quarterly Report Nov 09 2016
ETF’s with exposure to Agenus, Inc. : October 31, 2016 Oct 31 2016
Agenus, Inc. :AGEN-US: Earnings Analysis: Q3, 2016 By the Numbers : October 28, 2016 Oct 28 2016
Agenus (AGEN) Reports Wider-than-Expected Loss in Q3 Oct 28 2016
Agenus downgraded by H.C. Wainwright Oct 28 2016
Agenus 3Q Loss $41M, or 47 Cents a Share (AGEN) Oct 28 2016
Agenus (AGEN) Reports Narrower-than-Expected Q3 Loss Oct 27 2016
Agenus reports 3Q loss Oct 27 2016
Agenus reports 3Q loss Oct 27 2016
Agenus Reports Third Quarter Financial Results and Recent Highlights Oct 27 2016
AGENUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 27 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)